Companies / Regulus Therapeutics Inc.
Regulus Therapeutics Inc.
RGLSCIK 1505512
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Nov 30, 2021 | Papadopoulos Stelios Director | Grant Grant or award | Common Stock | $800.0K | +2.2M +78.26% | 5,061,929 | low |
| Dec 4, 2020 | Papadopoulos Stelios Director | Grant Grant or award | Common Stock | $500.0K | +794K +38.78% | 2,839,707 | low |
| Mar 14, 2024 | Papadopoulos Stelios Director | Grant Grant or award | Common Stock | $400.0K | +250K +34.32% | 978,388 | low |
| Jan 9, 2025 | Hagan Joseph P CEO | Grant Grant or award | Common Stock | $297.5K | +219K +383.02% | 275,862 | low |
| Apr 13, 2023 | Papadopoulos Stelios Director | Grant Grant or award | Common Stock | $200.0K | +222K +43.90% | 728,388 | low |
| Jan 13, 2025 | Hagan Joseph P CEO | Sell Open-market sale | Common Stock | $145.6K | -115K -34.12% | 222,572 | medium |
| Jun 3, 2025 | Klassen Preston Executive | Buy Open-market buy | Common Stock | $95.9K | +12K +33.28% | 48,055 | medium |
| Jan 9, 2025 | Aker Christopher Ray Executive | Grant Grant or award | Common Stock | $90.6K | +67K +735.70% | 75,681 | low |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| RGLS | common | 75915K309 |